+6281216825037 [email protected]

BioNTech — a COVID-19 vaccine manufacturer in partnership with Pfizer — announced its regulatory submission was subject to a cyber-attack from the European Medicines Agency on Wednesday, according to a brief statement on the agency’s website.

The hack is under investigation.


Pfizer/BioNTech vaccine documents were hacked

The European Medicines Agency (EMA) is working toward approving two COVID-19 vaccine candidates, expected to reach completion in two weeks, and the recent cyber-attack won’t affect this timeline, according to BioNTech, the BBC reports.

The EMA didn’t offer additional details on the extent or nature of the cyber-attack in a brief note on the hack on its website — except to say a full investigation was underway.

An agency spokesperson said it was still “functional,” reports the BBC. But BioNTech said it was told documents relevant to the COVID-19 vaccine were accessed, in a different statement on its website.

BioNTech said hack will have ‘no impact’ on vaccine review timeline

“Today, we were informed […] that the agency has been subject to a cyber-attack and that some documents relating to the regulatory submission for Pfizer and BioNTech’s COVID-19 vaccine candidate, BNT162b2, which has been stored on an EMA server, had been unlawfully accessed,” said the company’s statement.

“EMA has assured us that the cyber attack will have no impact on the timeline for its review,” added BioNTech’s release.

UPDATE Dec. 9, 3:20 PM EST: 

Regarding the possibility of medical study participants’ personal data security, BioNTech said it was “unaware” of any threat of comproim



This is breaking news about a cyber-attack on the EMA’s documents relevant to Pfizer/BioNTech’s COVID-19 vaccine candidate, so be sure to return here for more updates.

We have created an interactive page to demonstrate engineers’ noble efforts against COVID-19 across the world. If you are working on a new technology or producing any equipment in the fight against COVID-19, please send your project to us to be featured.

Source Article